Unbiased high-throughput drug combination screens reveal that PI3K-AKT-mTOR pathway inhibitors exert synergistic anticancer effects with BRD4 inhibitors against small cell lung cancer cells, and mTOR inhibitors exhibit the best synergy [52]. This evidence concerns the gene BRD4 and small cell lung carcinoma.